Advancing Light Scattering Assays for AAV Products
Presented by: Margaret Butko, Ph.D., Adverum
Presented Live: March 19, 2025
AAV-based gene therapy products are heterogeneous, composed of empty, partial, and full monomer capsid species as well as capsid aggregates and fragments. Tracking the relative abundance of these populations allows for greater control in delivering a consistent product to patients. This webinar describes a DLS method to monitor capsid aggregation, including generation of a capsid aggregation standard and bringing the method to a GMP setting. This webinar also describes an FFF-MALS method for quantifying the relative abundance of capsid aggregates. Finally, this webinar describes SEC-MALS as a platform method for quantifying the relative abundance of full capsids.